Rua Bioscience (RUA) H2 2025 earnings summary

Executive summary

• Revenue increased significantly to $1.51 million for the year ended 30 June 2025, up from $85,837 year-over-year.

• Net loss after tax narrowed to $3.46 million from $13.72 million year-over-year.

• Comprehensive loss for the year was $3.45 million, reflecting improved performance but continued losses.

• Expanded product portfolio into Germany, Australia, New Zealand, and the UK, with new launches and distribution agreements.

Financial highlights

• Total revenue and other income rose to $1.90 million from $321,678 year-over-year.

• Operating loss before net financing income improved to $3.30 million from $13.83 million year-over-year.

• Basic and diluted loss per share improved to $(0.02) from $(0.09) year-over-year.

• Net cash outflow from operating activities was $2.72 million, an improvement from $3.74 million the previous year.

Outlook and guidance

• Forecasts significant operating milestones in the next 12 months, including further product sales in the UK and expansion in Australia, Germany, Czechia, and New Zealand.

• Plans to establish Rua genetics in Canada, New Zealand, and Portugal.

• Ongoing efforts to achieve a sustainable operating model and reach profitability.